Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
The inhibition of apoptotic cell death in T cells through the dysregulated expression of BCL2 family members has been associated with the protection against the development of different autoimmune diseases. However, multiple mechanisms were proposed to be responsible for such protective effect. The purpose of this study was to explore the effect of the T-cell overexpression of BCL2A1, an anti-apoptotic BCL2 family member without an effect on cell cycle progression, in the development of collagen-induced arthritis. Our results demonstrated an attenuated development of arthritis in these transgenic mice. The protective effect was unrelated to the suppressive activity of regulatory T cells but it was associated with a defective activation of p38 mitogen-activated protein kinase in CD4+ cells after in vitro TCR stimulation. In addition, the in vitro and in vivo TH17 differentiation were impaired in BCL2A1 transgenic mice. Taken together, we demonstrated here a previously unknown role for BCL2A1 controlling the activation of CD4+ cells and their differentiation into pathogenic proinflammatory TH17 cells and identified BCL2A1 as a potential target in the control of autoimmune/inflammatory diseases.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4951111 | PMC |
| http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0159714 | PLOS |
Publication Analysis
Top Keywords
Similar Publications
Sensitivity of Pediatric Myelodysplastic Syndromes With Excess of Blasts With UBTF-TD to Venetoclax/Azacitidine.
Am J Hematol
September 2025
Department of Pediatric Hematology/Oncology, Cell and Gene Therapy, IRCCS Bambino Gesù Children's Hospital, Rome, Italy.
UBTF-TD has been reported in a significant percentage of childhood MDS-EB and has been associated with inferior survival compared to that of patients with the wild-type gene. We treated three consecutive pediatric patients affected by UBTF-TD MDS-EB with venetoclax and azacitidine (ven/aza) in combination as 28-day cycles on a compassionate use basis three consecutive pediatric patients affected by UBTF-TD MDS-EB as a bridge to allogeneic HSCT. Treatment with ven/aza was well-tolerated, and all patients responded to the ven/aza course, achieving CR with flow-cytometry negativity.
View Article and Find Full Text PDFUpregulation of EMP3 in acute myeloid leukemia: a study based on data mining, RT-qPCR and immunohistochemistry.
Discov Oncol
September 2025
Department of Hematology, The Second Affiliated Hospital of Guangxi Medical University, No.166, Daxue Road, Nanning, 530000, Guangxi Zhuang Autonomous Region, People's Republic of China.
Background: Epithelial Membrane Protein 3 (EMP3) has been associated with multiple malignancies, but its expression patterns and clinical significance in acute myeloid leukemia (AML) remain poorly characterized.
Methods: Public datasets were integrated to assess EMP3 mRNA expression levels in AML patients versus healthy donors, with validation performed using reverse transcription quantitative PCR (RT-qPCR). Protein expression was accessed through immunohistochemistry.
BCL2A1‑ and G0S2‑driven neutrophil extracellular traps: A protective mechanism linking preeclampsia to reduced breast cancer risk.
Oncol Rep
June 2025
Department of Obstetrics and Gynecology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region 530021, P.R. China.
Preeclampsia has been associated with a reduced risk of breast cancer (BC), but the mechanisms underlying this relationship remain unclear. It has been suggested that neutrophil extracellular traps (NETs), which are released upon neutrophil activation, play a key role in both preeclampsia and BC. To investigate this link, the single‑cell RNA sequencing dataset GSE173193 was analyzed and upregulated genes BCL2A1 and G0/G1 switch gene 2 (G0S2) were identified in neutrophils from preeclamptic placentas.
View Article and Find Full Text PDFA novel FOXM1-BCL2A1 axis determines unfavorable response to venetoclax in AML.
J Biol Chem
March 2025
University of Illinois at Chicago, Department of Medicine, Chicago, Illinois, USA. Electronic address:
Forkhead box M1 (FOXM1), a Forkhead family transcription factor, is often overexpressed in a variety of human cancers, including acute myeloid leukemia (AML), and is strongly associated with therapy resistance and unfavorable outcomes. In AML with NPM1 mutations, NPM1-FOXM1 complex sequesters FOXM1 in the cytoplasm and confers favorable treatment outcomes for AML patients because of FOXM1 inactivation. Inhibition of FOXM1 in AML cell lines and animal models of AML sensitizes AML cells to the BCL2 inhibitor, venetoclax.
View Article and Find Full Text PDFMulti-omics technologies and molecular biomarkers in brain tumor-related epilepsy.
CNS Neurosci Ther
April 2024
School of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou, China.
Article Synopsis
- Brain tumors significantly contribute to intractable epilepsy, particularly brain tumor-related epilepsy (BTRE), which poses a heavy burden on patients and healthcare costs.
- Multi-omics technologies have advanced research into the complex factors influencing BTRE, including genetic and molecular biomarkers, providing insights into its pathophysiological mechanisms.
- Key findings highlight the role of specific genes like BRAF and IDH in the development of BTRE, as well as potential biomarkers for diagnosis and treatment, indicating the necessity for novel approaches in managing this condition.